

/ / ()

*

()

Natingham Modification Bloom – Richardson

()

% /

% /

% / : Grade III

% / : Grade I

(EGFR)

()

()

(in situ)

(chronological)
 (Cross-Sectional)

(MIBI/Ki67/TU)
 (EGFR/cer B2/neu)
 % /) (P53/c-myc/cyclin)
 PS2 (CD
 nm23)

.()

Epidermal Growth Factor Receptor

EGFR . (EGFR)

% TGF- α EGF
 % EGFR .
 PBS %
 PBS () q c-ERBB
 H2O2 %

PBS .()

EGFR

EGFR ()	%	EGFR % EGFR GFR () %
EGFR		
EGFR % /		EGFR
EGFR		EGFR
() Seshardi		
() Tolgayocal		
EGFR	Tsutsui	EGFR Toi M
(Disease free survival)		Tsutsui
		() % /
		() % /
		EGFR
		()
		EGFR
EGFR		EGFR
		EGFR
EGFR		EGFR
		EGFR
		Pirinen

REFERENCES

1. Kumar V, Cotran R, Robbins S. *Basic Pathology*. 6th ed. Philadelphia: WB Saunders Company. 1997.
2. Sternberg SS. *Diagnostic Surgical Pathology*. 3rd ed. Philadelphia: Williams and Wilkms. 1999.
3. Decherney AH, Nathan L. *Current obstetric and gynecologic diagnosis and treatment*. 9th ed. New York: Lange McGraw- Hill.2003.
4. Berek JS. *Novak's Gynecology*. 13th ed. Philadelphia: Williams and Wilkins.2007.
5. Speroff L, Fritz MA. *Clinical Gynecologic Endocrinology and Infertility*.7th ed. Philadelphia: Williams and Wilkms. 2005.
6. Donegan WL. Tumor-related prognostic factors for breast cancer. *Cancer J Clin* 1997; 47: 28-51.
7. Val H, Losada J, Murua MA, Sarria R. Cell proliferation, nuclear ploidy, and EGFR and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma . *Cancer Genet Cytogenet* 2002;138(1):69-72.
8. Tol M, Osaki A, Yamada H, Toge T. EGM expression as a prognostic indicator in breast cancer. *Eur J Cancer* 1991; 27(8): 977-80.
9. Tsutui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of EGFR and its relationship to the estrogen receptor status in 1029 patients with breast cancer. *Breast Cancer Research and Treatment* 2002; 71: 67-75.
10. Pirmien R, Lipponen P, Syrianen K. Expression of EGFR in breast cancer as related to clinical, prognostic and cytometric factors. *Anticancer Res* 1995; 15(68): 2835-40.
11. Seshadri R, McLeay WR, Horsfall W, McCaul K. Prospective study of the prognostic significance of EGFR in primary breast cancer. *Int J Cancer* 1996; 69(1):23-7.
12. Ocal IT, Dolled-filhart M, Aquila TG, Camp RL, Rimm DL. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that Met expression is associated with worse outcome but is not correlated with EGFR family receptors. *Am Cancer Soc* 2003; 97(9):1841-8.
13. Kirkegaard T, McGlynn LM, Campbell FM, Müller S, Tovey SM, Dunne B, et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. *Clin Cancer Res* 2007; 13(5):1405-11.
14. Riedemann J, Sohail M, Macaulay VM. Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells. *Biochem Biophys Res Commun* 2007; 15: 230-3.
15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. *Arch Pathol Lab Med*. 2007 1; 131(1):18.
16. Fuchs IB, Siemer I, Buhler H, Schmider A. Epidermal growth factor receptor changes during breast cancer metastasis. *Anticancer Res* 2006; 26(6B):4397-401.

-
17. Johnston JB, Navaratnam S, Pitz MW. Targeting the EGFR pathway for cancer therapy. *Curr Med Chem.* 2006; 13(29): 3483-92.
 18. Homaei-Shandiz F, Ghavam-Nassiri MR, Sharifi N, Homaei-Shandiz AH, Taghizadeh-Kermani A, et al. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer. *Saudi Med J* 2006; 27(12): 1810-4.